AgriMetis™ Announces Second International Patent Filing to Provide Farmers Safer, Improved Tool Against Weeds

LUTHERVILLE, MD – February 11, 2019 – AgriMetis, LLC is pleased to announce that a second international patent cooperation treaty (PCT) filing related to its L-glufosinate (Glu-L™) program has been published. The Glu-L product family of broad-spectrum herbicides offers an improved alternative to the commercial racemic glufosinate currently being manufactured and sold, marking a milestone in innovation for the global agrichemical market.

The first patent family related to Glu-L includes issued US Patent 9,834,802 and describes methods to convert inactive D-glufosinate to active L-glufosinate.  The published PCT can be found at: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017151573.

This second Glu-L application describes improved methods to isolate L-glufosinate from the AgriMetis patented production process. These methods were developed using AgriMetis’ approach of intentionally combining synthetic biology, chemistry, and process engineering to solve problems facing the agrichemical industry. For more information on this PCT publication: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019018406.

Steven Tuttle, President and CEO of AgriMetis said, “As AgriMetis advances Glu-L toward the market, we continue to develop more efficient and lower cost approaches to making and isolating this important product. This new PCT publication not only describes interesting and useful science, but also exemplifies what is possible to achieve with close collaboration among AgriMetis’ scientists and those in our external network.  The chance to exercise our innovative approach to deliver an improved product to farmers for broad spectrum weed control is thrilling to all involved.”

The research and development team at AgriMetis continues to develop a comprehensive intellectual property portfolio to protect the novel approach to producing the active L-glufosinate from the racemic mixture of active L-glufosinate and inactive D-glufosinate. Previous patent application publications and the issued patent relating to important technologies from AgriMetis include:

http://www.agrimetis.com/blog-posts/2017/3/20/agrimetis-announces-publication-of-spinosyn-analog-patent-applications

http://www.agrimetis.com/blog-posts/2017/9/10/publication-of-l-glufosinate-patent-application-announced-by-agrimetis-1-bl7kn

http://www.agrimetis.com/blog-posts/2018/8/4/agrimetis-announces-publication-of-additional-spinometis-patent-applications

About AgriMetis:

AgriMetis is committed to working with leading agriculture companies and businesses to fill the emerging need for sustainable crop protection products through leading edge and advanced discovery, development and delivery methods. The AgriMetis technology platform is at the interface of synthetic biology, biochemistry, and chemistry, employing a multidisciplinary and integrated scientific approach, allowing access to areas of chemical space and production routes that are inaccessible to others. AgriMetis was formed in March 2014 and completed a Series B financing in December 2016 to fund agriculture chemical research and development by applying a biopharmaceutical model. With headquarters near Baltimore, Maryland, AgriMetis continues to grow and develop its technologies and capabilities. For more information, please visit http://www.agrimetis.com

This press release contains “forward-looking statements” concerning the development and commercialization of AgriMetis’ products, the potential benefits and attributes of such products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. AgriMetis undertakes no obligation to update any forward-looking statements for any reason.

Laurie Gunther